Find Clinical Trials

On this page, you will find different kinds of study results:

• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.

227 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL1-95031-006	Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects with Nonresectable or Metastatic IDH1-Mutant Cholangiocarcinoma	Ivosidenib	Phase 1-2	Cancers
AG881-C-002	Study of Orally Administered AG881 in Patients With Advanced Solid Tumors, Including Gliomas, With an…	vorasidenib	Phase 1	Cancers
S095032-211	Vorasidenib in combination with temozolomide (TMZ) in IDH-mutant glioma	vorasidenib	Phase 1-2	Cancers
S095031-178	Ivosidenib (IVO) monotherapy and azacitidine (AZA) monotherapy in patients with hypomethylating agent (HMA) naive myelodysplastic…	Ivosidenib	Phase 3	Cancers
CL2-95031-008	A Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in PreviouslyTreated Japanese Subjects with…	Ivosidenib	Phase 2	Cancers
S227928-180	A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in…	S227928	Phase 1-2	Cancers
S095031-210	Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic…	Cisplatin, Durvalumab, Gemcitabine, Ivosidenib	Phase 1-2	Cancers
S005190-213	Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers…	GLICLAZIDE MR	Phase 1	Metabolism
S221237-176	Comparative pharmacokinetic study of three prolonged release formulations and one immediate release formulation of S221237…	S221237	Phase 1	Neuropsychiatric Diseases
SPLFIO-174	Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung…	Cemiplimab (anti-PD1 antibody), S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), S095029 (anti-NKG2A antibody)	Phase 1-2	Cancers
CL1-95035-001	S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine…		Phase 1	Cancers
CL3-95031-007	Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With…	Ivosidenib	Phase 3	Cancers
S005190-170	Exploratory bioavailability of two formulations of gliclazide MR tablets 120 mg (I.R.I.S.) in healthy volunteers…	GLICLAZIDE	Phase 1	Metabolism
CL1-ONCO-001	An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis…	No drug	Phase 1	Cancers
AG881-C-004	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or…	vorasidenib	Phase 3	Cancers
	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or…	vorasidenib	Phase 3	Cancers
CL3-06593-018	Evaluation of the clinical efficacy and safety of perindopril 5 mg / indapamide 1.25 mg…	AMLODIPINE, INDAPAMIDE, PERINDOPRIL	Phase 3	Cardiovascular Diseases
SYM021-01	A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of…	Anti-PD-1	Phase 1	Cancers
CL1-95012-002	An open label, multicentre, positron emission tomography (PET) imaging study using Zirconium-89 to investigate the…	"S095012"	Phase 1	Cancers
CL3-LUSEO-001	Study assessing the glucose-lowering efficacy and safety of luseogliflozin on top of metformin in Caucasian…	Luseogliflozin	Phase 3	Metabolism
CL1-95032-005	Update in progress A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With…	S095032	Phase 1	Cancers
AG120-C-005	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable…	AG120, Ivosidenib	Phase 3	Cancers
CL3-05166-003	Evaluation of the clinical efficacy and safety of Amlodipine 5mg/ Bisoprolol fumarate 5mg /Perindopril arginine…	AMLODIPINE, BISOPROLOL, PERINDOPRIL, S05166	Phase 3	Cardiovascular Diseases
CL3-05179-002	Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or…	AMLODIPINE, BISOPROLOL, INDAPAMIDE, PERINDOPRIL, S05179	Phase 3	Cardiovascular Diseases
CL3-95026-001	A randomised, open-label, multi-centre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tipiracil to…	Futuximab, Modotuximab, S095026	Phase 3	Cancers

1 2 … 9 10 Next